CFTR and cystic fibrosis: Despite the success of CFTR pharmacotherapy, there are still 5–10% of CF patients who will not directly benefit from correctors and potentiators because they carry undruggable mutations, such as premature termination codons (PTCs) that lead to a truncated nonfunctional CFTR protein [2,3].